Versatope Therapeutics is using recombinant extracellular transport vesicles (rETVs) as a technology platform for cell-specific targeted delivery of molecules used in therapeutics. We are the first company to prove that a universal influenza vaccine may be feasible to provide durable immunity against multiple influenza strains with a single immunization.